Lu AH70212
Alternative Names: Lu-AH70212Latest Information Update: 18 Mar 2026
At a glance
- Originator Lundbeck A/S
- Class Sleep disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Narcolepsy
Most Recent Events
- 19 Feb 2026 Phase-I clinical trials in Narcolepsy (In volunteers) in France (unspecified route) (CTIS2025-522652-58-01)